Table S1 Clinical demographics of IFN-β-treated MS patients in the NEDA and EDA groups

<table>
<thead>
<tr>
<th></th>
<th>MS w/IFN-β</th>
<th>HCs (n = 44)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NEDA (n = 8)</td>
<td>EDA (n = 13)</td>
<td></td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>6 (75.0)</td>
<td>9 (69.2)</td>
<td>27 (61.4)</td>
</tr>
<tr>
<td>Age at examination, years</td>
<td>47.0 [44.5-53.8]</td>
<td>44.0 [41.0-46.5]</td>
<td>35.0 [32.3-43.8]</td>
</tr>
<tr>
<td>Age at disease onset, years</td>
<td>30.5 [25.5-34.8]</td>
<td>27.0 [23.5-34.0]</td>
<td>–</td>
</tr>
<tr>
<td>Disease duration at INF-β initiation, years</td>
<td>6.83 [1.38-10.3]</td>
<td>6.50 [2.29-12.9]</td>
<td>–</td>
</tr>
<tr>
<td>Disease duration at examination, years</td>
<td>15.8 [9.00-23.9]</td>
<td>15.2 [10.7-20.6]</td>
<td>–</td>
</tr>
<tr>
<td>Subtype (RRMS / SPMS / PPMS), n (%)</td>
<td>7/1/0 (87.5/12.5/0.0)</td>
<td>6/6/1 (46.2/46.2/7.7)</td>
<td>–</td>
</tr>
<tr>
<td>EDSS score at IFN-β initiation</td>
<td>3.0 [1.25-6.13]</td>
<td>2.5 [1.75-5.25]</td>
<td>–</td>
</tr>
<tr>
<td>EDSS score at examination</td>
<td>2.0 [1.13-2.75]</td>
<td>4.5 [2.0-6.25]</td>
<td>–</td>
</tr>
<tr>
<td>ΔEDSS</td>
<td>−0.5 [−1.5-0.0]</td>
<td>1.0 [0.25-2.5]</td>
<td>–</td>
</tr>
<tr>
<td>MSSS at examination</td>
<td>1.84 [0.57-3.65]</td>
<td>3.52 [1.99-7.39]</td>
<td>–</td>
</tr>
<tr>
<td>ΔMSSS</td>
<td>−2.69 [−5.16−1.16]</td>
<td>−0.20 [−1.69-0.96]</td>
<td>–</td>
</tr>
<tr>
<td>Years of IFN-β treatment</td>
<td>9.50 [5.50-14.5]</td>
<td>7.00 [4.50-8.50]</td>
<td>–</td>
</tr>
</tbody>
</table>

Values are the median [IQR] or count (%). ΔEDSS was calculated as the difference between EDSS scores at IFN-β initiation and at examination. ΔMSSS was the difference between MSSS at IFN-β initiation and at examination.
EDA = evidence of disease activity; EDSS = Expanded Disability Status Scale; HCs = healthy controls; IFN-β = interferon-β; IQR = interquartile ranges; MS = multiple sclerosis; MSSS = multiple sclerosis severity score; NEDA = no-evidence of disease activity; NS = not significant; PPMS = primary progressive MS; RRMS = relapsing-remitting MS; SPMS = secondary progressive MS; w/ = with.
**Table S2** Clinical demographics of untreated MS patients in the NEDA and EDA groups

<table>
<thead>
<tr>
<th></th>
<th>Untreated MS</th>
<th>p value</th>
<th>p value</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NEDA (n = 19)</td>
<td>EDA (n = 13)</td>
<td>HCs (n = 44)</td>
<td>NEDA vs. HCs</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>16 (84.2)</td>
<td>12 (92.3)</td>
<td>27 (61.4)</td>
<td>NS (0.086)</td>
</tr>
<tr>
<td>Age at examination, years</td>
<td>52.0 [38.0-62.0]</td>
<td>49.0 [35.5-55.5]</td>
<td>35.0 [32.3-43.8]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age at disease onset, years</td>
<td>31.0 [24.0-44.0]</td>
<td>31.0 [24.5-36.5]</td>
<td>35.0 [32.3-43.8]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Disease duration at examination, years</td>
<td>13.9 [8.2-26.9]</td>
<td>13.0 [4.6-21.0]</td>
<td>13.0 [4.6-21.0]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Subtype (RRMS/SPMS/PPMS), n (%)</td>
<td>14/3/2 (73.7/15.8/10.5)</td>
<td>10/2/1 (76.9/15.4/7.7)</td>
<td>10/2/1 (76.9/15.4/7.7)</td>
<td>NS</td>
</tr>
<tr>
<td>EDSS score at 2 years before examination*</td>
<td>2.0 [0.0-4.0]</td>
<td>1.0 [0.0-5.4]</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>EDSS score at examination</td>
<td>2.0 [0.0-4.0]</td>
<td>2.0 [1.0-5.5]</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>ΔEDSS*</td>
<td>0.0 [0.0-0.0]</td>
<td>1.00 [1.0-2.5]</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>MSSS at 2 years before examination*</td>
<td>2.13 [0.25-5.44]</td>
<td>1.27 [0.06-6.16]</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>MSSS at examination</td>
<td>1.80 [0.21-5.16]</td>
<td>2.85 [0.88-8.89]</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>ΔMSSS*</td>
<td>-0.09 [-0.62-0.03]</td>
<td>1.18 [0.33-1.44]</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Values are the median [IQR] or count (%). ΔEDSS was calculated as the difference between EDSS scores at 2 years before examination and at examination. ΔMSSS was the difference between MSSS at 2 years before examination and at examination.

*The data of 5 patients are missing because of a lack of data before the onset.

EDA = evidence of disease activity; EDSS = Expanded Disability Status Scale; HCs = healthy controls; IFN-β = interferon-β; IQR = interquartile ranges; MS = multiple sclerosis; MSSS = multiple sclerosis severity score; NEDA = no-evidence of disease activity; NS = not significant; PPMS = primary progressive MS; RRMS = relapsing-remitting MS; SPMS = secondary progressive MS.
<table>
<thead>
<tr>
<th></th>
<th>Untreated MS</th>
<th></th>
<th>p value</th>
<th></th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RRMS (n = 26)</td>
<td>PMS (n = 9)</td>
<td></td>
<td></td>
<td>RRMS (n = 13)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>23 (88.5)</td>
<td>7 (77.8)</td>
<td>NS</td>
<td></td>
<td>9 (69.2)</td>
</tr>
<tr>
<td>Age at examination, years</td>
<td>45.0 [36.5-54.0]</td>
<td>56.0 [46.5-67.5]</td>
<td>0.043</td>
<td></td>
<td>46.0 [43.0-47.0]</td>
</tr>
<tr>
<td>Age at disease onset, years</td>
<td>31.0 [27.8-36.0]</td>
<td>29.0 [19.0-55.0]</td>
<td>NS</td>
<td></td>
<td>30.0 [25.0-34.0]</td>
</tr>
<tr>
<td>EDSS score at examination</td>
<td>1.5 [0.0-3.0]</td>
<td>7.0 [6.25-7.25]</td>
<td>&lt;0.001</td>
<td></td>
<td>2.0 [1.5-2.5]</td>
</tr>
<tr>
<td>MSSS at examination</td>
<td>1.57 [0.24-2.99]</td>
<td>7.97 [6.56-8.60]</td>
<td>&lt;0.001</td>
<td></td>
<td>1.64 [0.61-2.88]</td>
</tr>
<tr>
<td>Disease duration at IFN-β initiation, years</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
<td>7.1 [1.7-12.9]</td>
</tr>
<tr>
<td>EDSS score at IFN-β initiation</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
<td>2.0 [1.0-3.5]</td>
</tr>
<tr>
<td>MSSS at IFN-β initiation</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
<td>3.69 [1.32-5.62]</td>
</tr>
<tr>
<td>Years of IFN-β treatment</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
<td>7.0 [4.0-9.5]</td>
</tr>
</tbody>
</table>

Values are the median [IQR] or count (%).

EDSS = Expanded Disability Status Scale; IFN-β = interferon-β; IQR = interquartile ranges; MS = multiple sclerosis; MSSS = MS severity score; NS = not significant; PMS = progressive MS; RRMS = relapsing-remitting MS; w/ = with.
<table>
<thead>
<tr>
<th>In total CD4⁺ T cells</th>
<th>Untreated MS  (n = 35)</th>
<th>MS w/ IFN-β  (n = 21)</th>
<th>HCs  (n = 44)</th>
<th>$p$ value (K-W test)</th>
<th>$p^{adj}$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Untreated MS vs. HCs</td>
</tr>
<tr>
<td>T naïve (CCR7⁺CD45RA⁺)</td>
<td>45.3 [38.8-59.4]</td>
<td>51.2 [41.2-58.8]</td>
<td>49.4 [36.1-56.9]</td>
<td>NS</td>
<td>−</td>
</tr>
<tr>
<td>Tcm (CCR7⁺CD45RA⁻)</td>
<td>27.9 [21.7-33.7]</td>
<td>26.7 [21.0-32.0]</td>
<td>25.7 [23.2-33.6]</td>
<td>NS</td>
<td>−</td>
</tr>
<tr>
<td>Teff (CCR7⁻CD45RA⁺)</td>
<td>2.82 [1.74-3.87]</td>
<td>2.87 [2.20-4.58]</td>
<td>2.51 [1.99-3.67]</td>
<td>NS</td>
<td>−</td>
</tr>
<tr>
<td>Activated T (HLA-DR⁺)</td>
<td>1.96 [1.50-3.07]</td>
<td>2.36 [1.72-3.02]</td>
<td>2.81 [1.59-3.57]</td>
<td>NS</td>
<td>−</td>
</tr>
<tr>
<td>Treg (CD25⁺CD127 low/−)</td>
<td>4.41 [2.83-5.95]</td>
<td>3.80 [3.50-5.82]</td>
<td>5.97 [4.34-6.87]</td>
<td>0.012</td>
<td>NS</td>
</tr>
</tbody>
</table>

Values are the median [IQR]. Percentages of each population in total CD4⁺ T cells are shown.

$p$ values (K-W test) were obtained by Kruskal-Wallis analyses, and if they were statistically significant, then $p^{adj}$ values were calculated using multivariate linear regression analyses adjusted for age and sex.

HCs = healthy controls; IFN-β = interferon-β; IQR = interquartile ranges; K-W = Kruskal-Wallis; MS = multiple sclerosis; NS = not significant; Tcm = central memory T cells; Teff = effector T cells; Tem = effector memory T cells; T naïve = naïve T cells; Treg = regulatory T cells; w/ = with.
### Table S5 Comparison of the percentages of CD8+ T cell subsets between the untreated MS group, IFN-β-treated MS group and healthy controls

<table>
<thead>
<tr>
<th>In total CD8+ T cells</th>
<th>Untreated MS (n = 35)</th>
<th>MS w/ IFN-β (n = 21)</th>
<th>HCs (n = 44)</th>
<th>p value (K-W test)</th>
<th>p&lt;sub&gt;adj&lt;/sub&gt; value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Untreated MS vs. HCs</td>
</tr>
<tr>
<td>Tnaive (CCR7&lt;sup&gt;+&lt;/sup&gt;CD45RA&lt;sup&gt;+&lt;/sup&gt;)</td>
<td>28.1 [17.7-53.8]</td>
<td>46.0 [28.6-64.3]</td>
<td>44.4 [33.6-54.2]</td>
<td>0.035</td>
<td>NS</td>
</tr>
<tr>
<td>Tcm (CCR7&lt;sup&gt;+&lt;/sup&gt;CD45RA&lt;sup&gt;-&lt;/sup&gt;)</td>
<td>5.14 [3.04-9.04]</td>
<td>8.68 [5.51-12.0]</td>
<td>5.55 [3.72-7.58]</td>
<td>0.017</td>
<td>NS</td>
</tr>
<tr>
<td>Tem (CCR7&lt;sup&gt;-&lt;/sup&gt;CD45RA&lt;sup&gt;-&lt;/sup&gt;)</td>
<td>37.6 [26.7-46.6]</td>
<td>26.7 [16.9-45.3]</td>
<td>29.2 [23.9-44.0]</td>
<td>NS</td>
<td>–</td>
</tr>
<tr>
<td>Teff (CCR7&lt;sup&gt;-&lt;/sup&gt;CD45RA&lt;sup&gt;+&lt;/sup&gt;)</td>
<td>15.9 [8.70-25.2]</td>
<td>11.6 [6.68-17.4]</td>
<td>12.8 [8.16-22.8]</td>
<td>NS</td>
<td>–</td>
</tr>
</tbody>
</table>

Values are the median [IQR]. Percentages of each population in total CD8+ T cells are shown. 

p values (K-W test) were obtained by Kruskal-Wallis analyses, and if they were statistically significant, then p<sub>adj</sub> values were calculated using multivariate linear regression analyses adjusted for age and sex.

HCs = healthy controls; IFN-β = interferon-β; IQR = interquartile ranges; K-W = Kruskal-Wallis; MS = multiple sclerosis; NS = not significant; Tcm = central memory T cells; Teff = effector T cells; Tem = effector memory T cells; Tnaive = naïve T cells; w/ = with.
Table S6 Comparison of the percentages of cytokine-producing αβ T cell subsets between the untreated MS group, IFN-β-treated MS group and healthy controls

<table>
<thead>
<tr>
<th></th>
<th>Untreated MS (n = 35)</th>
<th>MS w/ IFN-β (n = 21)</th>
<th>HCs (n = 44)</th>
<th>p value (K-W test)</th>
<th>p\textsuperscript{adj} value</th>
<th>Untreated MS vs. HCs</th>
<th>MS w/ IFN-β vs. HCs</th>
<th>Untreated MS vs. MS w/ IFN-β</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>In CD4\textsuperscript{+} T cells</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-17A\textsuperscript{+}</td>
<td>0.24 [0.16-0.58]</td>
<td>0.37 [0.27-0.61]</td>
<td>0.55 [0.25-1.11]</td>
<td>0.004</td>
<td>0.017</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>IFN-γ\textsuperscript{+}</td>
<td>5.77 [2.04-8.24]</td>
<td>6.70 [2.38-10.3]</td>
<td>9.42 [4.59-14.6]</td>
<td>NS (0.052)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>IL-4\textsuperscript{+}</td>
<td>1.70 [0.83-2.91]</td>
<td>1.64 [1.04-2.69]</td>
<td>2.76 [1.67-4.31]</td>
<td>0.018</td>
<td>0.011</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>GM-CSF\textsuperscript{+}</td>
<td>1.36 [0.76-3.19]</td>
<td>1.90 [1.56-3.71]</td>
<td>5.40 [1.19-7.91]</td>
<td>0.002</td>
<td>0.002</td>
<td>0.034</td>
<td>NS (0.081)</td>
<td>NS</td>
</tr>
<tr>
<td>IL-17A\textsuperscript{+}IFN-γ\textsuperscript{+}</td>
<td>0.03 [0.01-0.08]</td>
<td>0.04 [0.02-0.08]</td>
<td>0.06 [0.02-0.14]</td>
<td>0.039</td>
<td>NS (0.093)</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>IL-17A\textsuperscript{+}GM-CSF\textsuperscript{+}</td>
<td>0.04 [0.01-0.08]</td>
<td>0.05 [0.03-0.11]</td>
<td>0.15 [0.07-0.32]</td>
<td>&lt;0.001</td>
<td>0.010</td>
<td>NS (0.081)</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td><strong>In CD8\textsuperscript{+} T cells</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-17A\textsuperscript{+}</td>
<td>0.17 [0.08-0.28]</td>
<td>0.24 [0.14-0.39]</td>
<td>0.16 [0.10-0.31]</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>IFN-γ\textsuperscript{+}</td>
<td>18.7 [10.1-37.6]</td>
<td>15.6 [4.97-33.0]</td>
<td>27.2 [16.1-38.3]</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>IL-17A\textsuperscript{+}IFN-γ\textsuperscript{+}</td>
<td>0.05 [0.02-0.10]</td>
<td>0.06 [0.02-0.07]</td>
<td>0.07 [0.02-0.14]</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Values are the median [IQR]. Percentages of each population are shown.

p values (K-W test) were obtained by Kruskal-Wallis analyses, and if they were statistically significant, then p\textsuperscript{adj} values were calculated using multivariate linear regression analyses adjusted for age and sex.

GM-CSF = granulocyte macrophage colony-stimulating factor; HCs = healthy controls; IFN = interferon; IL = interleukin; IQR = interquartile ranges; K-W = Kruskal-Wallis; MS = multiple sclerosis; NS = not significant; w/ = with.
Table S7 Comparison of the percentages of cytokine-producing γδ T cell subsets in IFN-β-treated MS patients stratified to the NEDA or EDA groups

<table>
<thead>
<tr>
<th></th>
<th>MS w/IFN-β</th>
<th>NEDA (n = 8)</th>
<th>EDA (n = 13)</th>
<th>HCs (n = 44)</th>
<th>p value (K-W test)</th>
<th>p&lt;sub&gt;adj&lt;/sub&gt; value</th>
<th>NEDA vs. HCs</th>
<th>EDA vs. HCs</th>
<th>NEDA vs. EDA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>In V&lt;sup&gt;δ1&lt;/sup&gt;&lt;sup&gt;+&lt;/sup&gt;γδT cells</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-17A&lt;sup&gt;+&lt;/sup&gt;</td>
<td>0.58 [0.10-1.04]</td>
<td>0.27 [0.00-1.20]</td>
<td>0.18 [0.01-0.72]</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>IFN-γ&lt;sup&gt;+&lt;/sup&gt;</td>
<td>35.2 [17.7-56.9]</td>
<td>25.0 [5.75-34.3]</td>
<td>45.8 [24.4-60.8]</td>
<td>0.015 NS</td>
<td>0.001</td>
<td>0.001 NS</td>
<td>0.001 (0.070)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>IL-17A&lt;sup&gt;+&lt;/sup&gt;IFN-γ&lt;sup&gt;+&lt;/sup&gt;</td>
<td>0.21 [0.04-0.75]</td>
<td>0.11 [0.00-0.55]</td>
<td>0.08 [0.00-0.31]</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>IL-17A&lt;sup&gt;+&lt;/sup&gt;IFN-γ&lt;sup&gt;−&lt;/sup&gt;</td>
<td>64.8 [42.9-82.0]</td>
<td>75.0 [65.3-93.2]</td>
<td>54.1 [39.1-75.5]</td>
<td>0.014 NS</td>
<td>0.001</td>
<td>0.001 NS</td>
<td>0.001 (0.074)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>In V&lt;sup&gt;δ2&lt;/sup&gt;&lt;sup&gt;+&lt;/sup&gt;γδT cells</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-17A&lt;sup&gt;+&lt;/sup&gt;</td>
<td>0.00 [0.00-2.10]</td>
<td>0.00 [0.00-0.82]</td>
<td>0.13 [0.01-0.52]</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>IFN-γ&lt;sup&gt;+&lt;/sup&gt;</td>
<td>39.9 [23.1-74.7]</td>
<td>32.4 [18.8-58.7]</td>
<td>83.6 [69.1-92.7]</td>
<td>&lt;0.001</td>
<td>0.003</td>
<td>&lt;0.001</td>
<td>NS</td>
<td>0.001</td>
<td>–</td>
</tr>
<tr>
<td>IL-17A&lt;sup&gt;+&lt;/sup&gt;IFN-γ&lt;sup&gt;+&lt;/sup&gt;</td>
<td>0.00 [0.00-1.56]</td>
<td>0.00 [0.00-0.18]</td>
<td>0.11 [0.01-0.42]</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>IL-17A&lt;sup&gt;+&lt;/sup&gt;IFN-γ&lt;sup&gt;−&lt;/sup&gt;</td>
<td>60.1 [25.0-76.9]</td>
<td>67.6 [40.8-78.9]</td>
<td>16.0 [7.30-30.9]</td>
<td>&lt;0.001</td>
<td>0.003</td>
<td>&lt;0.001</td>
<td>NS</td>
<td>0.001</td>
<td>NS</td>
</tr>
<tr>
<td><strong>In V&lt;sup&gt;δ1&lt;/sup&gt;-V&lt;sup&gt;δ2&lt;/sup&gt;&lt;sup&gt;+&lt;/sup&gt;γδT cells</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-17A&lt;sup&gt;+&lt;/sup&gt;</td>
<td>1.03 [0.39-2.13]</td>
<td>0.79 [0.31-1.87]</td>
<td>1.24 [0.66-2.81]</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>IFN-γ&lt;sup&gt;+&lt;/sup&gt;</td>
<td>31.1 [14.6-52.8]</td>
<td>14.2 [8.88-27.3]</td>
<td>47.1 [32.5-58.2]</td>
<td>&lt;0.001</td>
<td>NS</td>
<td>&lt;0.001</td>
<td>0.033</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>IL-17A&lt;sup&gt;+&lt;/sup&gt;IFN-γ&lt;sup&gt;+&lt;/sup&gt;</td>
<td>0.44 [0.19-0.80]</td>
<td>0.34 [0.00-0.65]</td>
<td>0.35 [0.19-1.22]</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>IL-17A&lt;sup&gt;+&lt;/sup&gt;IFN-γ&lt;sup&gt;−&lt;/sup&gt;</td>
<td>68.6 [46.4-84.7]</td>
<td>84.0 [72.2-88.6]</td>
<td>51.7 [41.3-66.9]</td>
<td>&lt;0.001</td>
<td>NS</td>
<td>&lt;0.001</td>
<td>0.038</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Values are the median [IQR]. Percentages of each population are shown.
$p$ values (K-W test) were obtained by Kruskal-Wallis analyses, and if they were statistically significant, then $p^{adj}$ values were calculated using multivariate linear regression analyses adjusted for age and sex.

EDA = evidence of disease activity; HCs = healthy controls; IFN = interferon; IL = interleukin; IQR = interquartile ranges; K-W = Kruskal-Wallis; MS = multiple sclerosis; NEDA = no-evidence of disease activity; NS = not significant; w/ = with.
Table S8 Comparison of the percentages of γδ T cell subsets in untreated MS patients stratified to the NEDA or EDA groups

<table>
<thead>
<tr>
<th></th>
<th>Untreated MS</th>
<th>HCs (n = 44)</th>
<th>p value (K-W test)</th>
<th>p&lt;sub&gt;adj&lt;/sub&gt; value</th>
<th>NEDA vs. HCs</th>
<th>EDA vs. HCs</th>
<th>NEDA vs. EDA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NEDA (n = 19)</td>
<td>EDA (n = 13)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vδ1&lt;sup&gt;+&lt;/sup&gt;</td>
<td>29.0 [14.0-71.5]</td>
<td>31.9 [17.5-51.8]</td>
<td>18.4 [11.6-34.2]</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Vδ1&lt;sup&gt;+&lt;/sup&gt;Vγ9&lt;sup&gt;+&lt;/sup&gt;</td>
<td>4.00 [1.63-16.3]</td>
<td>3.91 [1.14-8.07]</td>
<td>2.15 [1.12-4.71]</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Vδ1&lt;sup&gt;+&lt;/sup&gt;Vγ9&lt;sup&gt;−&lt;/sup&gt;</td>
<td>23.1 [10.2-42.3]</td>
<td>30.4 [15.0-41.4]</td>
<td>15.5 [8.47-31.5]</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Vδ2&lt;sup&gt;+&lt;/sup&gt;</td>
<td>38.5 [5.30-56.2]</td>
<td>29.9 [15.6-51.7]</td>
<td>54.9 [31.7-65.9]</td>
<td>0.024</td>
<td>NS</td>
<td>NS (0.076)</td>
<td>NS</td>
</tr>
<tr>
<td>Vδ2&lt;sup&gt;+&lt;/sup&gt;Vγ9&lt;sup&gt;+&lt;/sup&gt;</td>
<td>37.9 [5.16-55.9]</td>
<td>29.8 [14.5-51.0]</td>
<td>54.3 [31.1-65.7]</td>
<td>0.021</td>
<td>NS</td>
<td>NS (0.073)</td>
<td>NS</td>
</tr>
<tr>
<td>Vδ2&lt;sup&gt;+&lt;/sup&gt;Vγ9&lt;sup&gt;−&lt;/sup&gt;</td>
<td>0.19 [0.11-0.46]</td>
<td>0.14 [0.03-0.67]</td>
<td>0.08 [0.03-0.29]</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Vδ1&lt;sup&gt;−&lt;/sup&gt;Vδ2&lt;sup&gt;−&lt;/sup&gt;</td>
<td>21.1 [14.1-27.3]</td>
<td>28.2 [17.3-43.0]</td>
<td>22.8 [17.1-30.3]</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Vδ1&lt;sup&gt;−&lt;/sup&gt;Vδ2&lt;sup&gt;−&lt;/sup&gt;Vγ9&lt;sup&gt;+&lt;/sup&gt;</td>
<td>1.61 [0.30-2.69]</td>
<td>1.10 [0.46-3.15]</td>
<td>2.42 [1.25-3.83]</td>
<td>NS (0.069)</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Vδ1&lt;sup&gt;−&lt;/sup&gt;Vδ2&lt;sup&gt;−&lt;/sup&gt;Vγ9&lt;sup&gt;−&lt;/sup&gt;</td>
<td>20.0 [11.0-25.7]</td>
<td>27.5 [17.2-36.9]</td>
<td>18.1 [10.7-26.4]</td>
<td>NS (0.065)</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Values are the median [IQR]. Percentages of each population in total γδ T cells are shown.

p values (K-W test) were obtained by Kruskal-Wallis analyses, and if they were statistically significant, then p<sub>adj</sub> values were calculated using multivariate linear regression analyses adjusted for age and sex.

EDA = evidence of disease activity; HCs = healthy controls; IFN-β = interferon-β; IQR = interquartile ranges; K-W = Kruskal-Wallis; MS = multiple sclerosis; NEDA = no-evidence of disease activity; NS = not significant.
<table>
<thead>
<tr>
<th>B Cell Subset</th>
<th>Untreated MS</th>
<th>HCs (n = 44)</th>
<th>p value (K-W test)</th>
<th>p^{adj} value</th>
<th>NEDA vs. HCs</th>
<th>EDA vs. HCs</th>
<th>NEDA vs. EDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naïve (CD27⁻IgD⁺)</td>
<td>46.3 [27.1-54.0]</td>
<td>53.8 [38.8-59.5]</td>
<td>51.8 [41.4-60.6]</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Memory (CD27⁺)</td>
<td>13.4 [9.82-24.4]</td>
<td>19.9 [12.6-36.2]</td>
<td>22.7 [16.9-29.9]</td>
<td>0.024</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>CS⁺ Memory (CD27⁺IgD⁻)</td>
<td>11.2 [8.84-22.0]</td>
<td>18.0 [11.1-32.7]</td>
<td>18.8 [14.4-25.2]</td>
<td>NS (0.060)</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>CS⁻ Memory (CD27⁺IgD⁺)</td>
<td>1.65 [0.72-2.68]</td>
<td>2.28 [1.86-3.80]</td>
<td>3.49 [2.49-4.67]</td>
<td>&lt;0.001</td>
<td>0.043</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Plasmablasts (CD38⁺⁺CD20⁻)</td>
<td>0.25 [0.12-0.49]</td>
<td>0.61 [0.28-1.48]</td>
<td>0.37 [0.24-0.67]</td>
<td>0.030</td>
<td>NS</td>
<td>NS (0.064)</td>
<td>0.008</td>
</tr>
<tr>
<td>Transitional (CD24⁺⁺CD38⁺⁺)</td>
<td>3.16 [1.80-4.14]</td>
<td>2.50 [0.58-6.09]</td>
<td>3.14 [2.32-4.45]</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Values are the median [IQR]. Percentages of each population in total B cells are shown.

*p values (K-W test) were obtained by Kruskal-Wallis analyses, and if they were statistically significant, then p^{adj} values were calculated using multivariate linear regression analyses adjusted for age and sex.

CS⁺ = class-switched; CS⁻ = non-class-switched; EDA = evidence of disease activity; HCs = healthy controls; IFN-β = interferon-β; IQR = interquartile ranges; K-W = Kruskal-Wallis; MS = multiple sclerosis; NEDA = no-evidence of disease activity; NS = not significant.
Table S10 Comparison of the percentages of γδ T cell subsets between RRMS and PMS patients

<table>
<thead>
<tr>
<th>Cell Subset</th>
<th>Untreated MS</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th>MS w/IFN-β</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RRMS (n = 26)</td>
<td>PMS (n = 9)</td>
<td>p value</td>
<td>RRMS (n = 13)</td>
<td>PMS (n = 8)</td>
<td>p value</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vδ1+</td>
<td>27.0 [13.3-47.4]</td>
<td>49.7 [16.8-77.2]</td>
<td>NS</td>
<td>29.6 [14.9-52.0]</td>
<td>24.5 [12.7-43.6]</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vδ1+Vγ9+</td>
<td>3.26 [0.93-5.31]</td>
<td>11.1 [2.64-20.9]</td>
<td>NS (0.062)</td>
<td>3.22 [1.88-6.70]</td>
<td>2.68 [1.52-3.90]</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vδ1+Vγ9−</td>
<td>22.5 [9.64-38.0]</td>
<td>36.7 [10.6-51.2]</td>
<td>NS</td>
<td>23.5 [9.18-42.7]</td>
<td>21.9 [11.4-35.3]</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vδ2+</td>
<td>37.0 [18.6-54.8]</td>
<td>7.34 [2.11-54.3]</td>
<td>NS</td>
<td>11.0 [3.75-24.2]</td>
<td>33.4 [11.2-44.5]</td>
<td>NS (0.076)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vδ2+Vγ9+</td>
<td>36.0 [18.0-54.6]</td>
<td>7.34 [1.87-54.0]</td>
<td>NS</td>
<td>10.6 [3.55-23.8]</td>
<td>32.2 [11.1-44.4]</td>
<td>NS (0.089)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vδ2+Vγ9−</td>
<td>0.20 [0.11-0.51]</td>
<td>0.06 [0.00-0.27]</td>
<td>NS</td>
<td>0.21 [0.11-0.72]</td>
<td>0.06 [0.00-0.20]</td>
<td>NS (0.099)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vδ1−Vδ2−</td>
<td>26.2 [16.4-42.9]</td>
<td>22.7 [14.5-38.7]</td>
<td>NS</td>
<td>43.6 [22.8-63.4]</td>
<td>32.3 [27.7-43.2]</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vδ1−Vδ2−Vγ9+</td>
<td>1.89 [0.38-3.57]</td>
<td>0.66 [0.10-1.31]</td>
<td>0.050</td>
<td>2.22 [0.33-2.82]</td>
<td>0.88 [0.25-1.48]</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vδ1−Vδ2−Vγ9−</td>
<td>23.8 [15.4-34.8]</td>
<td>21.3 [13.8-37.0]</td>
<td>NS</td>
<td>41.4 [19.5-60.1]</td>
<td>31.7 [25.4-42.5]</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Values are the median [IQR]. Percentages of each population in total γδ T cells are shown.

IFN-β = interferon-β; IQR = interquartile ranges; MS = multiple sclerosis; NS = not significant; PMS = progressive MS; RRMS = relapsing-remitting MS; w/ = with.
| In total CD4⁺ T cells | Untreated MS | | | | MS w/IFN-β | | | |
|---|---|---|---|---|---|---|---|---|---|
| | RRMS (n = 26) | PMS (n = 9) | p value | RRMS (n = 13) | PMS (n = 8) | p value |
| Tnaive (CCR7⁺CD45RA⁺) | 55.8 [43.4-66.2] | 38.8 [32.9-41.8] | 0.002 | 51.9 [44.4-57.1] | 44.6 [33.2-60.6] | NS |
| Tcm (CCR7⁺CD45RA⁻) | 25.3 [21.2-33.5] | 30.4 [28.0-38.0] | NS | 26.7 [19.4-34.1] | 27.5 [21.7-31.6] | NS |
| Tem (CCR7⁻CD45RA⁻) | 17.6 [12.1-22.1] | 26.4 [20.8-35.0] | 0.004 | 16.4 [14.7-19.0] | 22.8 [10.7-34.7] | NS |
| Teff (CCR7⁻CD45RA⁺) | 2.75 [1.73-3.52] | 2.85 [1.77-7.60] | NS | 2.87 [2.19-5.39] | 2.76 [2.15-3.03] | NS |
| Activated T (HLA-DR⁺) | 1.86 [1.31-2.86] | 2.55 [1.84-4.01] | NS (0.070) | 2.36 [1.83-2.91] | 2.05 [1.06-4.73] | NS |

Values are the median [IQR]. Percentages of each population in total CD4⁺ T cells are shown.

IFN-β = interferon-β; IQR = interquartile ranges; MS = multiple sclerosis; NS = not significant; PMS = progressive MS; RRMS = relapsing-remitting MS; Tcm = central memory T cells; Teff = effector T cells; Tem = effector memory T cells; Tnaive = naïve T cells; Treg = regulatory T cells; w/ = with.
Table S12 Comparison of the percentages of CD8+ T cell subsets between RRMS and PMS patients

<table>
<thead>
<tr>
<th>In total CD8+ T cells</th>
<th>Untreated MS</th>
<th>p value</th>
<th>MS w/IFN-β</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RRMS (n = 26)</td>
<td>PMS (n = 9)</td>
<td></td>
<td>RRMS (n = 13)</td>
</tr>
<tr>
<td>Tnaive (CCR7+CD45RA+)</td>
<td>31.7 [19.6-58.2]</td>
<td>21.9 [6.77-28.7]</td>
<td>NS (0.052)</td>
<td>52.1 [43.0-64.3]</td>
</tr>
<tr>
<td>Tem (CCR7 CD45RA-)</td>
<td>36.4 [25.0-46.0]</td>
<td>43.5 [34.8-55.6]</td>
<td>NS</td>
<td>21.1 [16.9-30.6]</td>
</tr>
</tbody>
</table>

Values are the median [IQR]. Percentages of each population in total CD8+ T cells are shown.

IFN-β = interferon-β; IQR = interquartile ranges; MS = multiple sclerosis; NS = not significant; PMS = progressive MS; RRMS = relapsing-remitting MS; Tcm = central memory T cells; Teff = effector T cells; Tem = effector memory T cells; Tnaive = naïve T cells; Treg = regulatory T cells; w/ = with.
<table>
<thead>
<tr>
<th>Naïve (CD27&lt;sup&gt;+&lt;/sup&gt;IgD&lt;sup&gt;+&lt;/sup&gt;)</th>
<th>RRMS (n = 26)</th>
<th>PMS (n = 9)</th>
<th>p value</th>
<th>RRMS (n = 13)</th>
<th>PMS (n = 8)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naïve (CD27&lt;sup&gt;+&lt;/sup&gt;IgD&lt;sup&gt;+&lt;/sup&gt;)</td>
<td>45.5 [27.7-56.3]</td>
<td>52.0 [29.6-60.7]</td>
<td>NS</td>
<td>55.6 [50.3-63.2]</td>
<td>35.1 [18.0-40.9]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CS&lt;sup&gt;+&lt;/sup&gt; memory (CD27&lt;sup&gt;+&lt;/sup&gt;IgD&lt;sup&gt;+&lt;/sup&gt;)</td>
<td>15.3 [10.2-25.6]</td>
<td>10.7 [7.72-18.1]</td>
<td>NS</td>
<td>6.93 [5.31-11.3]</td>
<td>13.2 [7.48-20.9]</td>
<td>NS (0.060)</td>
</tr>
<tr>
<td>CS&lt;sup&gt;-&lt;/sup&gt; memory (CD27&lt;sup&gt;+&lt;/sup&gt;IgD&lt;sup&gt;+&lt;/sup&gt;)</td>
<td>2.27 [0.98-2.78]</td>
<td>1.65 [0.57-2.50]</td>
<td>NS</td>
<td>1.13 [0.89-1.67]</td>
<td>0.92 [0.64-2.86]</td>
<td>NS</td>
</tr>
<tr>
<td>Plasmablasts (CD38&lt;sup&gt;high&lt;/sup&gt;CD20&lt;sup&gt;-&lt;/sup&gt;)</td>
<td>0.28 [0.11-0.59]</td>
<td>0.49 [0.16-1.65]</td>
<td>NS</td>
<td>0.36 [0.21-0.47]</td>
<td>0.31 [0.28-1.14]</td>
<td>NS</td>
</tr>
<tr>
<td>Transitional (CD24&lt;sup&gt;high&lt;/sup&gt;CD38&lt;sup&gt;high&lt;/sup&gt;)</td>
<td>2.83 [1.88-6.00]</td>
<td>3.20 [0.48-7.00]</td>
<td>NS</td>
<td>6.36 [4.16-10.5]</td>
<td>1.52 [1.05-5.14]</td>
<td>0.015</td>
</tr>
</tbody>
</table>

Values are the median [IQR]. Percentages of each population in total B cells are shown. CS<sup>+</sup> = class-switched; CS<sup>-</sup> = non-class-switched; IFN-β = interferon-β; IQR = interquartile ranges; MS = multiple sclerosis; NS = not significant; PMS = progressive MS; RRMS = relapsing-remitting MS; w/ = with.
**Table S14** Comparison of the percentages of cytokine-producing γδ T cell subsets between RRMS and PMS patients

<table>
<thead>
<tr>
<th></th>
<th>Untreated MS</th>
<th></th>
<th>MS w/IFN-β</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RRMS (n = 26)</td>
<td>PMS (n = 9)</td>
<td>p value</td>
<td>RRMS (n = 13)</td>
<td>PMS (n = 8)</td>
<td>p value</td>
</tr>
<tr>
<td>In Vδ1⁺γδ T cells</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-17A⁺</td>
<td>0.13 [0.00-0.41]</td>
<td>0.12 [0.00-0.50]</td>
<td>NS</td>
<td>0.54 [0.02-1.03]</td>
<td>0.33 [0.04-1.16]</td>
<td>NS</td>
</tr>
<tr>
<td>IFN-γ⁺</td>
<td>35.9 [16.5-40.8]</td>
<td>36.6 [12.4-54.9]</td>
<td>NS</td>
<td>25.0 [7.14-45.2]</td>
<td>32.7 [11.9-37.9]</td>
<td>NS</td>
</tr>
<tr>
<td>IL-17A⁺IFN-γ⁺</td>
<td>0.03 [0.00-0.14]</td>
<td>0.00 [0.00-0.12]</td>
<td>NS</td>
<td>0.17 [0.00-0.66]</td>
<td>0.18 [0.00-0.58]</td>
<td>NS</td>
</tr>
<tr>
<td>IL-17A⁻IFN-γ⁻</td>
<td>64.1 [58.5-81.8]</td>
<td>63.4 [45.0-87.4]</td>
<td>NS</td>
<td>75.0 [54.8-91.9]</td>
<td>66.8 [62.1-87.7]</td>
<td>NS</td>
</tr>
<tr>
<td>In Vδ2⁺γδ T cells</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-17A⁺</td>
<td>0.07 [0.00-0.45]</td>
<td>0.00 [0.00-0.47]</td>
<td>NS</td>
<td>0.00 [0.00-2.63]</td>
<td>0.00 [0.00-1.15]</td>
<td>NS</td>
</tr>
<tr>
<td>IL-17A⁺IFN-γ⁺</td>
<td>0.00 [0.00-0.29]</td>
<td>0.00 [0.00-0.06]</td>
<td>NS</td>
<td>0.00 [0.00-1.06]</td>
<td>0.00 [0.00-0.47]</td>
<td>NS</td>
</tr>
<tr>
<td>IL-17A⁻IFN-γ⁻</td>
<td>48.5 [14.9-87.3]</td>
<td>62.5 [36.8-93.2]</td>
<td>NS</td>
<td>61.9 [43.4-75.4]</td>
<td>50.4 [27.2-88.5]</td>
<td>NS</td>
</tr>
<tr>
<td>In Vδ1⁻Vδ2⁻γδ T cells</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-17A⁺</td>
<td>0.63 [0.27-1.38]</td>
<td>0.53 [0.25-1.43]</td>
<td>NS</td>
<td>0.73 [0.40-1.72]</td>
<td>1.22 [0.20-1.93]</td>
<td>NS</td>
</tr>
<tr>
<td>IL-17A⁺IFN-γ⁺</td>
<td>0.23 [0.03-0.53]</td>
<td>0.17 [0.00-0.51]</td>
<td>NS</td>
<td>0.34 [0.18-0.48]</td>
<td>0.65 [0.00-0.92]</td>
<td>NS</td>
</tr>
<tr>
<td>IL-17A⁻IFN-γ⁻</td>
<td>70.6 [58.9-85.6]</td>
<td>75.8 [57.9-93.5]</td>
<td>NS</td>
<td>83.9 [56.7-87.8]</td>
<td>75.1 [67.3-91.9]</td>
<td>NS</td>
</tr>
</tbody>
</table>

Values are the median [IQR]. Percentages of each population are shown.
IFN = interferon; IL = interleukin; IQR = interquartile ranges; MS = multiple sclerosis; NS = not significant; PMS = progressive MS; RRMS = relapsing-remitting MS; w/ = with.
Table S15 Comparison of the percentages of cytokine-producing αβ T cell subsets between RRMS and PMS patients

<table>
<thead>
<tr>
<th></th>
<th>Untreated MS</th>
<th></th>
<th></th>
<th>MS w/IFN-β</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RRMS (n = 26)</td>
<td>PMS (n = 9)</td>
<td>p value</td>
<td>RRMS (n = 13)</td>
<td>PMS (n = 8)</td>
<td>p value</td>
</tr>
<tr>
<td><strong>In CD4$^+$ T cells</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-17A$^+$</td>
<td>0.24 [0.15-0.61]</td>
<td>0.29 [0.11-0.47]</td>
<td>NS</td>
<td>0.39 [0.27-0.57]</td>
<td>0.33 [0.27-0.62]</td>
<td>NS</td>
</tr>
<tr>
<td>IL-4$^+$</td>
<td>1.48 [0.80-2.81]</td>
<td>2.46 [1.06-3.85]</td>
<td>NS</td>
<td>1.64 [1.04-2.44]</td>
<td>2.12 [1.06-3.55]</td>
<td>NS</td>
</tr>
<tr>
<td>GM-CSF$^+$</td>
<td>1.47 [0.76-3.22]</td>
<td>1.36 [0.48-4.01]</td>
<td>NS</td>
<td>2.59 [1.78-4.12]</td>
<td>1.68 [1.28-2.13]</td>
<td>NS</td>
</tr>
<tr>
<td>IL-17A$^+$IFN-γ$^+$</td>
<td>0.03 [0.01-0.06]</td>
<td>0.03 [0.01-0.05]</td>
<td>NS</td>
<td>0.04 [0.02-0.09]</td>
<td>0.04 [0.02-0.08]</td>
<td>NS</td>
</tr>
<tr>
<td>IL-17A$^+$GM-CSF$^+$</td>
<td>0.04 [0.01-0.10]</td>
<td>0.04 [0.01-0.05]</td>
<td>NS</td>
<td>0.08 [0.03-0.15]</td>
<td>0.04 [0.02-0.05]</td>
<td>NS (0.089)</td>
</tr>
<tr>
<td><strong>In CD8$^+$ T cells</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-17A$^+$</td>
<td>0.19 [0.10-0.37]</td>
<td>0.13 [0.06-0.17]</td>
<td>NS</td>
<td>0.25 [0.16-0.63]</td>
<td>0.18 [0.13-0.25]</td>
<td>NS</td>
</tr>
<tr>
<td>IL-17A$^+$IFN-γ$^+$</td>
<td>0.05 [0.02-0.12]</td>
<td>0.04 [0.01-0.08]</td>
<td>NS</td>
<td>0.06 [0.02-0.13]</td>
<td>0.04 [0.03-0.06]</td>
<td>NS</td>
</tr>
</tbody>
</table>

Values are the median [IQR]. Percentages of each population are shown.

GM-CSF = granulocyte macrophage colony-stimulating factor; IFN = interferon; IL = interleukin; IQR = interquartile ranges; MS = multiple sclerosis; NS = not significant; PMS = progressive MS; RRMS = relapsing-remitting MS; w/ = with.